Fri, May
86 New Articles

D&B David and Baias Advises Fiterman Pharma on Sale of Uractiv Portfolio to Terapia

D&B David and Baias Advises Fiterman Pharma on Sale of Uractiv Portfolio to Terapia

  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

PwC's Romanian affiliate D&B David and Baias has advised Fiterman Pharma on the sale of its Uractiv product portfolio to Sun Pharma company Terapia. KPMG Legal affiliate Toncescu si Asociatii reportedly advised the buyer.

The transaction remains contingent on regulatory approval.

According to Sun Pharma, the Uractiv portfolio comprises food supplements including minerals, vitamins, and adjuvants, cosmetics, and medical devices used for maintaining urinary tract health.

Fiterman Pharma is a Romanian pharmaceutical company providing therapeutic solutions to patients. Sun Pharma’s Romanian subsidiary Terapia is a pharmaceutical company with a manufacturing facility in Cluj-Napoca.

"Uractiv is a 100% Romanian product, highly appreciated by the medical community and pharmacists, which has reached annual sales of approximately USD 8.7 million and will benefit from the support of Sun Pharma to become a global reference product," PwC Romania director George Ureche commented.

"This transaction confirms the quality and performance of Fiterman Pharma products," Fiterman Pharma CEO Patricia Fiterman commented. "Uractiv, like all other Fiterman Pharma products, has been created with perseverance, passion, and dedication, constantly being inspired by patients to create innovative and high-quality products that suit their needs. We will continue to invest in research and innovation, in the continuous development of new products to cover a wide range of therapeutic areas."

The D&B David and Baias team included Managing Partner Sorin David and Managing Associate Romana Petre.